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Abstract
Background: Left ventricular dysfunction is common after coronary artery bypass graft and valve
replacement surgeries and is often treated with inotropic drugs to maintain adequate hemodynamic
status. In this study, we aimed to identify the demographic, clinical, laboratory, echocardiographic
and hemodynamic factors that are associated with use of inotropic drugs in patients undergoing
concomitant coronary artery bypass graft and aortic valve replacement surgery.
Methods: The study included 97 patients who had undergone concomitant coronary artery bypass
graft and aortic valve replacement at Regions Hospital, University of Minnesota Medical School
from January 2006 to December 2008. All data were collected retrospectively after reviewing
electronic medical records. Inotropic support was defined as the use of dopamine [greater than or
equal to] 5 ug/kg/min; any dose of epinephrine, norepinephrine, dobutamine, and milrinone at the
separation from cardiopulmonary bypass.
Results: Inotropic support was used in a total of 50 patients (52%) at the separation from
cardiopulmonary bypass. Average age of the patients requiring inotropic support was 72.2 +/- 8.8
years. The study identified four significant, independent predictors of inotrope use: (1) Cardiac
index [less than or equal to]2.5 L/min/m2, (2) LVEDP [greater than or equal to] 20 mm Hg, (3) LVEF
[less than or equal to]40%, and (4) CKD stage 3 to 5.
Conclusion:  We identified four independent risk factors for postoperative use of inotropic
support in patients undergoing concomitant coronary artery bypass graft and arotic valve
replacement surgery at the separation from cardiopulmonary bypass. The study results will be
helpful to prospectively identify patients who will likely to require inotropic support at the
separation from cardiopulmonary bypass.
Background
The incidence of inotrope support is proportionally
higher in patients undergoing combined coronary artery
bypass graft (CABG) and valve surgery as compared to
CABG alone[1]. Left ventricular dysfunction often occurs
after cardiopulmonary bypass (CPB), requiring the use of
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inotropic drugs to achieve adequate hemodynamic status
[2]. In contrast to patients with chronic ischemic heart dis-
ease, left ventricular dysfunction in patients with moder-
ate-to-severe valvular heart disease does not improve
immediately after surgery [1,3]. In patients with normal
preoperative ventricular function, contractile dysfunction
can occur between 4–6 hours after surgery, and usually
resolves around 24 hours postoperatively [4]. Although
many clinicians choose to treat patients prophylactically
with inotropic drugs[5], these drugs should be adminis-
tered selectively as use of these drugs subjects the patients
to an increased risk of tachycardia, dysarhythmia, and
myocardial ischemia[6,7].
Older age, reduced ejection fraction, female gender, cardi-
omegaly, history of congestive heart failure, emergency
operation, recent myocardial infarction, prolonged dura-
tion of CPB or aortic clamping, and left main coronary
artery disease were found to be risk factors associated with
need for inotropic support[2,8,9]. Pathophysiologic
changes associated with moderate-to-severe valvular heart
disease are longstanding and risk factors for inotropic sup-
port are likely to be different in patients undergoing con-
comitant CABG and valve replacement. A randomized,
double-blinded study, by Butterworth et al., showed that
the specific valve disease did not influence use of ino-
tropic support after heart valve surgery [2].
The purpose of our study was to identify the demographic,
clinical, laboratory, echocardiographic and hemody-
namic factors that are associated with the use of inotropic
support during separation from CPB in patients undergo-
ing concomitant coronary artery bypass grafting (CABG)
and aortic valve replacement (AVR) surgery.
Methods
After institutional review board approval, detailed clini-
cal, laboratory, echocardiographic and hemodynamic
data were retrospectively examined. All patients had tran-
sthoracic echocardiography (TTE), right and left heart
catheterizations and coronary angiogram within one
month prior to the surgical procedure. A comprehensive
transesophageal echocardiography (TEE) was performed
in all patients before cardiopulmonary bypass.
Patients who had concomitant coronary artery bypass
graft surgery (CABG) and aortic valve replacement (AVR),
without requiring preoperative inotropic support or an
intra-aortic balloon pump (IABP) were included. The
study includes 97 patients (54 men and 43 women) who
underwent concomitant CABG and AVR surgery from Jan-
uary, 2006 to December 2008 at the Regions Hospital of
University Minnesota Medical School.
Electronic medical records of all patients were reviewed.
Age, sex, body mass index (BMI), preoperative medication
use and New York Heart Association (NYHA) class prior
to the surgical procedure were collected. Hemoglobin and
creatinine level prior to surgical procedure were recorded.
A decrease in hemoglobin was calculated by recording the
second hemoglobin level collected routinely within 6
hours after the surgical procedure. Chronic kidney disease
(CKD) was assessed by glomerular filtration rate (GFR), as
recommended by National Health and Nutrition Exami-
nation Survey (NHANES) [10]. We included chronic kid-
ney disease stage 3 to stage 5 with a GFR less than 60 mL/
min per 1.73 m2 in the study for analysis. GFR was calcu-
lated by using Modification of Diet in Renal Disease study
equation (MDRD) [11].
Transthoracic echocardiography (TTE) results were
reviewed and the following data were collected: left ven-
tricular ejection fraction (LVEF), wall motion abnormali-
ties, moderate-to-severe mitral regurgitation (MR), left
ventricular hypertrophy (LVH) and presence of pulmo-
nary hypertension. Patients with hypokinesia, akinesia or
dyskinesia in the echocardiographic (TTE) report were
included as having wall motion abnormalities. Mitral
regurgitation was reported as mild, moderate or severe.
Only patients with moderate-to- severe MR were included
in the study for analysis.
Results of the right and left heart catheterization were
reviewed and following data were collected: left ventricu-
lar end diastolic pressure (LVEDP) and cardiac index (CI).
All surgical procedures were conducted under general
endotracheal anesthesia with midline sternotomy approach.
Full heparinization was carried out by an anesthesiologist,
with a goal of activated clotting time of over 400. The Patient
was placed in cardiopulmonary bypass and retrograde cardi-
oplegia was delivered. Cold ice slush was used for topic myo-
cardial protection. Patient was systemically drifted to 31–33
degree celsius throughout the cross- clamp time. Aortic valve
replacement and coronary artery bypass graft were per-
formed with standard techniques. After completion of AVR
and CABG, aortic cross clamp was released. Temporary atrial
and ventricular pacing wires were placed in a standard fash-
ion. After appropriate rest period and gradual rewarming, the
patient was weaned from cardiopulmonary bypass. Pro-
tamine was given to reverse the heparin effect and the patient
was decannulated. After adequate hemostasis was achieved,
the patient was transferred to the surgical intensive care unit.
Inotropic support was defined as the use of dopamine ≥ 5
μg/kg/min; any dose of epinephrine, norepinephrine,
dobutamine, or milrinone. None of the patients received
IABP support during the separation from CPB.
All patients were followed-up until March 31, 2009 and
mortality data and cause of death were collected.Journal of Cardiothoracic Surgery 2009, 4:24 http://www.cardiothoracicsurgery.org/content/4/1/24
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All statistical analyses were performed with Fischer's exact
test and a logistic regression analysis. A p value < 0.05 was
considered significant. Statistical analyses were conducted
using STATA 10.0 software (STATA Statistics/Data analy-
sis, Texas, USA)
Results
Ninety-seven patients underwent concomitant CABG and
AVR between January 2006 and December 2008. The
demographics of this patient group are displayed in Table
1. The percentage of men (58%) was higher than women
(42%) and the average age was 71.8 ± 10.1 years. Forty
seven percent of patients had diabetes mellitus and 70%
had hypertension. Pre-operative NYHA class assessment
showed 11% patients were in class II, 69% in class III and
20% were in class IV. Seventy four (76%) patients had
aortic stenosis, 16 (17%) patients had aortic regurgitation
and 7 (7%) patients had both aortic stenosis and regurgi-
tation.
Of 97 patients, 50(52%) patients required inotropic sup-
port at the separation of CPB. Women had slightly higher
need of inotropic support than men (27% vs 25%). The
average age of the patients requiring inotropic support
was 72.2 ± 8.8 years.
Univariate analysis showed that patients ≥ 70 years old
were more likely to get inotropic support (p = 0.02).
Obese patients with BMI ≥ 30 Kg/m2 and patients with
CKD stage 3 to 5 were associated with increased use of
inotropic support (p = 0.04 and p = 0.02 respectively).
Analysis of the preoperative echocardiographic (TTE) data
showed that patients with left ventricular ejection fraction
(LVEF) ≤ 40% were more likely to receive inotropic sup-
port (p = 0.001). Presence of pulmonary hypertension (p
= 0.69), moderate-to-severe mitral regurgitation (MR) (p
= 0.37), left ventricular hypertrophy (LVH) (p = 0.11) and
wall motion abnormalities (p = 0.86) were not associated
with an increased use of inotropic support. Neither sex (p
= 0.43) nor a preoperative diagnosis of diabetes (p = 0.61)
appeared to be associated with the use of inotropic sup-
port. All patients had their hemoglobin level checked
within 6 hours after the surgical procedure. A postopera-
tive drop of hemoglobin ≥ 6 gm/dl compared to preoper-
ative value, was found to have higher use of inotropic
support (p = 0.02). Preoperative use of beta-blockade was
not associated with an increased use of inotropic support
(p = 0.23).
Analysis of hemodynamic data showed that patients with
preoperative left ventricular end diastolic pressure
(LVEDP) ≥ 20 mm Hg and cardiac index (CI) ≤ 2.5 liters
per minute squared body surface area(L/min/m2) were
found to be highly associated with increased use of ino-
tropic support (p = 0.006 and 0.001 respectively). Univar-
iate predictors of inotrope use are displayed in Table 2.
Stepwise multivariate logistic regression analysis identi-
fied 4 significant, independent predictors of inotrope use
at separation from CPB (Table 3). Cardiac index ≤ 2.5 L/
min/m2 (odds ratio: 3.1, 95% confidence interval {1.13–
8.4}), LVEDP ≥ 20 mm Hg (3.58{1.16–9.03}), LVEF ≤
40% (2.76{1.11–6.86}), and CKD stage 3–5 (3.26{1.07–
9.95}) were all associated with inotropic support neces-
sity in patients who had undergone concomitant CABG
and AVR at the separation of CPB.
Postoperatively, out of 97 patients, 16 patients (16.5%)
developed paroxysmal atrial fibrillation (11 with ino-
tropic support and 5 without inotropic support), 7
patients (7%) developed non-sustained ventricular tachy-
cardia (5 with inotropic support and 2 without iniotropic
support), 4 patients (4%) developed acute renal failure
(all with inotropic support) and 3(3%) patients were
diagnosed with gram negative pneumonia (2 with ino-
tropic support and one without inotropic support). Three
patients (3%) developed postoperative mediastinal bleed-
ing (2 with inotropic support and one without inotropic
support) and all required reoperation to control bleeding.
Six patients (6%) developed postoperative sick sinus syn-
drome (3 with inotropic support and 3 without inotropic
support) and required permanent pacemaker placement.
Eight patients (8%) developed postoperative acute
Table 1: Patient Demographics
Age in years (± SD) 71.8 ± 10.1
Sex
Male 56 (58%)
Female 41 (42%)
Diabetes Mellitus 46 (47%)
Hypertension 68 (70%)
NYHA class
II 11 (11%)
III 67 (69%)
IV 19 (20%)
Aortic stenosis (AS) 74 (76%)
Aortic regurgitation (AR) 16 (17%)
Both AS and AR 7(7%)Journal of Cardiothoracic Surgery 2009, 4:24 http://www.cardiothoracicsurgery.org/content/4/1/24
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decompensated heart failure and required aggressive
intravenous diuresis (all with inotropic support).
Table 4 shows the causes of death of all patients, days
from the surgical procedure and whether or not they
required inotropic support after the surgery. Out of 97
patients who underwent concomitant CABG and AVR, 10
patients died after the surgical procedures. One patient
died within 24 hours after the surgical procedure from
congestive heart failure and required inotropic support
after the surgery. One patient died of congestive heart fail-
ure on the second postoperative day and required ino-
tropic support after the surgery. Out of total ten deaths, 8
patients died after the hospital discharge.
Discussion
In a retrospective study of 97 patients undergoing concomi-
tant CABG and AVR, 52% received inotropic support. We
have identified 4 independent preoperative risk factors for
the use of inotropic support at the separation from CPB. Car-
diac index ≤ 2.5 L/min/m2, LVEDP ≥ 20 mm Hg, LVEF ≤
40% and CKD stage 3 to 5 were all associated with an
increased use of inotropes. The results of the study will help
cardiothoracic surgeons, anesthesiologists and intensivists to
prospectively identify those patients who will likely to
require inotropic support at the separation from CPB. Com-
pared to previous published reports, the availability of
hemodynamic data is the strength of the study. Coronary
angiogram, right and left heart catheterizations are routinely
Table 2: Univariate Predictors of Inotrope Use
Inotropic support group(n = 50) Noninotropic support group(n = 47) P value
Age (≥ 70 years) 31 (32%) 18 (19%) 0.02
Sex
Male 24(25%) 19(20%) 0.43
Women 26(27%) 28(29%)
BMI ≥ 30 28(29%) 14(14%) 0.04
Diabetes Mellitus 21(22%) 25(26%) 0.61
CKD stage 3–5 (GFR<60 mL/min/1.73 m2) 14(14%) 5(5%) 0.02
Pulmonary hypertension 18(19%) 15(15%) 0.69
LVEF ≤ 40% 45(46%) 31(32%) 0.001
LVH 36(37%) 43(44%) 0.11
Moderate to severe MR 21(22%) 15(15%) 0.37
Wall motion abnormalities 16(16%) 14(14%) 0.86
Drop of hemoglobin ≥ 6 gm/dl 29(30%) 16(16%) 0.02
Pre-operative use of beta blocker 26(27%) 31(32%) 0.23
LVEDP ≥ 20 mm Hg 45(46%) 31(32%) 0.006
CI ≤ 2.5 L/min/m2 29(30%) 15(15%) 0.001
Abbreviations: BMI, body mass index; CKD, chronic kidney disease; MR, mitral regurgitation; LVEF, left ventricular ejection fraction; LVH, left 
ventricular hypertrophy; LVEDP, left ventricular end diastolic pressure; CI, cardiac index
Table 3: Multivariate Predictors of Inotrope Use
Variable Odds Ratio(95% Confidence Interval) P Value
Cardiac index ≤ 2.5 L/min/m2 3.1(1.13–8.4) 0.03
LVEDP ≥ 20 mm Hg 3.58(1.16–9.03) 0.02
LVEF ≤ 40% 2.76(1.11–6.86) 0.01
CKD stage 3–5(GFR<60 mL/min/1.73 m2 3.26(1.07–9.95) 0.04Journal of Cardiothoracic Surgery 2009, 4:24 http://www.cardiothoracicsurgery.org/content/4/1/24
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performed in patients undergoing concomitant CABG and
AVR and the additional hemodynamic data will be very use-
ful in identifying those high risk patients. In a study of 1,009
patients conducted by McKinlay et al., it was found that inci-
dence of inotrope use was greater in patients undergoing
combined CABG and valve surgery as compared to CABG
alone and combined CABG and valve surgery had longer
cross-clamp time [1]. We did not include cross-clamp time
and duration of CPB in our analysis as these data were not
consistently found in our electronic medical records. In
patients with moderate-to-severe aortic stenosis, left ven-
tricular hypertrophy and reduced left ventricular compliance
do not improve immediately after valve replacement due to
persistent high afterload. Similarly, in patients with aortic
valve insufficiency, left ventricular dilatation persists even
after aortic valve replacement [2]. In patients with longstand-
ing coronary artery disease and moderate-to-severe valvular
heart disease, left ventricular dysfunction likely will be
greater as compared to either alone.
Left ventricular dysfunction, as evidenced by reduced ejec-
tion fraction and low cardiac index, was found to be an
independent predictor of inotropic support in our study.
Left ventricular dysfunction was found to be a powerful
predictor of inotrope use in earlier studies in isolated
CABG or valve replacement surgery [8]. LVEF<35% was
found to be an independent predictor of inotropic sup-
port in patients undergoing CABG in the study conducted
by McKinlay et al [1]. Rao et al. studied a cohort of 4558
consecutive patients undergoing isolated CABG surgery
and found several risk factors for increased use of ino-
tropic support, including left ventricular ejection fraction
<20%, age >70 years and female gender Although ven-
tricular dysfunction after CPB is largely a transient phe-
nomenon related to ischemia, left ventricular dilatation
and reduced compliance, poor LV function continues to
be one of the most significant predictors of post-operative
inotropic support [9].
Advancing age was found to be a significant risk factor of
inotrope use in the previous studies [2,8,9] and our study
showed the similar result. In the univariate analysis, age ≥
70 years was significantly associated with inotrope use,
which was similar to the result found in the study con-
ducted by Rao et al [9]. We did not find any significant
association between particular gender and use of inotrope
as compared to increased risk in female gender in the
study by Rao et al [9].
Elevated LVEDP was shown to be an independent predic-
tor of mortality after cardiac surgery independently of
LVEF [12]. One frequent cause of elevated LVEDP is left
ventricular hypertrophy (LVH), which is a risk factor for
diastolic dysfunction [13]. LVH was present in 81% of our
study patients. We did not include diastolic dysfunction
as a risk factor in our study as it was not consistently men-
tioned as "normal" or "abnormal" in the echocardio-
graphic (TTE and TEE) reports. LVEDP could be associated
with systolic dysfunction, but patients with normal systo-
lic function and elevated LVEDP might be at higher risk of
mortality after cardiac surgery because of the deleterious
effect of elevated LVEDP with associated filling abnormal-
ities [12]. These abnormal loading conditions may predis-
pose the patient very sensitive to perioperative, often
abrupt changes in loading conditions with hypovolaemia
on one hand and volume overload on the other [12,14].
Obesity is well known to be major risk factor for cardio-
vascular disease and in our study we have shown obesity
to be a predictor of postoperative inotrope use in the uni-
variate analysis. In a retrospective cohort study, Pan et al.
concluded that obesity in diabetic patients is an inde-
pendent predictor of increased postoperative morbidity
after CABG surgery [15]. CKD stage 3 to 5, with GFR < 60
mL/min/1.73 m2 was an independent predictor of ino-
trope use in our study population. In a study published by
Yeo et al. GFR was found to be a significant risk factor for
operative mortality in patients undergoing CABG and
CKD stages 3, 4, and 5 were progressively associated with
increased operative mortality [16].
Out of total ten deaths in our study population, two
patients died in the same hospital admission and both of
these patients required inotropic support after the surgical
Table 4: Causes of death of all patients undergoing concomitant CABG and AVR
Inotropic support Days from the surgery Cause of death
Yes 1 Congestive heart failure
Yes 3 Congestive heart failure
No 183 Congestive heart failure
No 227 Colon cancer
Yes 281 Septicemia
Yes 347 Congestive heart failure
No 546 Esophageal cancer
No 581 Septicemia
No 738 Congestive heart failure
No 756 Gastrointestinal bleedingPublish with BioMed Central    and   every 
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procedures. Although, it might be possible that inotropic
support is associated with higher postoperative mortality
in patients undergoing concomitant CABG and AVR, a
prospective study with larger number of patients will be
required to better establish this hypothesis.
Our study, inevitably, has limitations. The study was ret-
rospective and data were obtained from a single institu-
tion. It was not conducted in a controlled, prospective,
randomized fashion. We have retrospectively reviewed
the results of echocardiography and cardiac catheteriza-
tion reports which were performed and read by different
cardiologists. There is a possibility of observer bias. Intia-
tion of inotrope might be at discretion of attending
anesthesiologists or intensivists and thus, selection bias
also cannot be overlooked.
In conclusion, low ejection fraction and left ventricular
dysfunction are frequently observed after CPB. Immediate
effects of CPB on LV systolic function are well known, but
the effects on diastolic dysfunction are less clear [17].
We believe that results of our study may be used to pro-
spectively identify patients undergoing concomitant
CABG and AVR who will likely to require inotropic sup-
port at the separation of CPB.
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